| Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site S Chen, JL Wu, Y Liang, YG Tang, HX Song, LL Wu, YF Xing, N Yan, ... Cancer cell 39 (2), 225-239. e8, 2021 | 152 | 2021 |
| Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations Y Tang, H Song, Z Wang, S Xiao, X Xiang, H Zhan, L Wu, J Wu, Y Xing, ... Cell Reports 39 (2), 110622, 2022 | 16 | 2022 |
| Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties H Song, J Wu, Y Tang, Y Dai, X Xiang, Y Li, L Wu, J Wu, Y Liang, Y Xing, ... Science Translational Medicine 15 (690), eabn9155, 2023 | 14 | 2023 |
| Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation N Yan, Y Li, Y Xing, J Wu, J Li, Y Liang, Y Tang, Z Wang, H Song, H Wang, ... EMBO reports 23 (6), e54147, 2022 | 10 | 2022 |
| PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy PG Miller, AS Sperling, C Mayerhofer, ME McConkey, JM Ellegast, ... Blood, 2023 | 6 | 2023 |
| AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity Y Liang, Q An, H Song, Y Tang, S Xiao, J Wu, N Yan, B Yu, X Cao, M Lu Journal of Medicinal Chemistry, 2023 | 4 | 2023 |
| Decitabine activates type I interferon signaling to inhibit p53‐deficient myeloid malignant cells J Wu, Y Li, J Wu, H Song, Y Tang, N Yan, L Wu, S Zhang, CK Chang, ... Clinical and translational medicine 11 (11), 2021 | 2 | 2021 |
| Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study H Wang, Z Wang, Z Wang, X Li, Y Li, N Yan, L Wu, Y Liang, J Wu, H Song, ... Frontiers of Medicine, 1-18, 2023 | | 2023 |
